{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:17:39Z","timestamp":1791062259125,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jconrel.2006.12.002","type":"journal-article","created":{"date-parts":[[2006,12,9]],"date-time":"2006-12-09T12:15:14Z","timestamp":1165666514000},"page":"204-215","source":"Crossref","is-referenced-by-count":101,"title":["Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?"],"prefix":"10.1016","volume":"118","author":[{"given":"JingXia","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunLei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenMin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanHui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CaiXia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanLi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongLi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.jconrel.2006.12.002_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(00)00131-9","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"46","author":"Jain","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2006.12.002_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0031-6997(24)01426-1","article-title":"Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors","volume":"51","author":"Drummond","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2006.12.002_bib3","series-title":"Liposomes: Rational Design","first-page":"309","article-title":"Preclinical development issues for lipid-based pharmaceuticals","author":"Swenson","year":"1999"},{"key":"10.1016\/j.jconrel.2006.12.002_bib4","series-title":"Liposomes: Rational Design","first-page":"343","article-title":"Liposomal anthracyclines: from basics to clinical approval of PEGylated liposomal doxorubicin","author":"Gabizon","year":"1999"},{"key":"10.1016\/j.jconrel.2006.12.002_bib5","series-title":"Liposomes: Rational Design","first-page":"363","article-title":"Clinical evaluation of liposomal anthracyclines","author":"Campos","year":"1999"},{"issue":"1","key":"10.1016\/j.jconrel.2006.12.002_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbamem.2006.01.009","article-title":"Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations","volume":"1758","author":"Johnston","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2006.12.002_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2005.03.007","article-title":"Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity","volume":"105","author":"Dos Santos","year":"2005","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2006.12.002_bib8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/jps.20332","article-title":"Optimization and characterization of a sphingomyelin\/cholesterol liposome formulation of vinorelbine with promising antitumor activity","volume":"94","author":"Semple","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2006.12.002_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0076-6879(05)91002-1","article-title":"Preparation, characterization, and biological analysis of liposomal formulations of vincristine","volume":"391","author":"Waterhouse","year":"2005","journal-title":"Methods Enzymol."},{"issue":"19","key":"10.1016\/j.jconrel.2006.12.002_bib10","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1158\/1078-0432.CCR-04-0221","article-title":"Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer","volume":"10","author":"Messerer","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.CCR-1131-03","article-title":"In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading","volume":"10","author":"Abraham","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2006.12.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/LPR-120017482","article-title":"Relevancy of drug loading to liposomal formulation therapeutic efficacy","volume":"13","author":"Barenholz","year":"2003","journal-title":"J. Liposome Res."},{"issue":"12","key":"10.1016\/j.jconrel.2006.12.002_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Safety"},{"issue":"5","key":"10.1016\/j.jconrel.2006.12.002_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-4157(92)90038-C","article-title":"Sterically stabilized liposomes","volume":"1113","author":"Woodle","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1020134521778","article-title":"Liposome clearance","volume":"22","author":"Ishida","year":"2002","journal-title":"Biosci. Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2006.12.002_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i3.20","article-title":"Pharmacokinetics of targeting with liposomes","volume":"19","author":"Harashima","year":"2002","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"5","key":"10.1016\/j.jconrel.2006.12.002_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","article-title":"Liposomal drug formulations: rationale for development and what we can expect for the future","volume":"56","author":"Allen","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2006.12.002_bib19","series-title":"Liposomes: Rational Design","first-page":"63","article-title":"Liposome pharmacokinetics: classical, sterically stabilized, cationic liposomes and immunoliposomes","author":"Allen","year":"1999"},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","article-title":"Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases","volume":"1151","author":"Haran","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2006.12.002_bib21","unstructured":"E. A. Forssen, Multiple step entrapment\/loading procedure for preparing lipophilic drug-containing liposomes, U.S. Patent 4,946,683, August 7, 1990."},{"key":"10.1016\/j.jconrel.2006.12.002_bib22","unstructured":"P. R. Cullis, M. J. Hope, M. B. Bally, Extrusion technique for producing unilamellar vesicles, U.S. Patent 5,008,050, April 16, 1991."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1570-0232(02)00395-1","article-title":"Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography","volume":"779","author":"Chin","year":"2002","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2006.12.002_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-3565(24)35297-8","article-title":"Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors","volume":"292","author":"Lim","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"21","key":"10.1016\/j.jconrel.2006.12.002_bib25","first-page":"5922","article-title":"Influence of vesicle size, lipid composition, and drug to lipid ratio on the biological activity of liposomal doxorubicin in mice","volume":"49","author":"Mayer","year":"1989","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.jconrel.2006.12.002_bib26","first-page":"6371","article-title":"Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies","volume":"50","author":"Gabizon","year":"1990","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jconrel.2005.10.011","article-title":"Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention","volume":"110","author":"Zhigaltsev","year":"2006","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2006.12.002_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0005-2736(98)00125-4","article-title":"Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H NMR study","volume":"1374","author":"Maurer","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.jconrel.2006.12.002_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0378-5173(89)90018-5","article-title":"Quantitative evaluation of targeted drug delivery systems","volume":"56","author":"Gupta","year":"1989","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2006.12.002_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-409X(99)00041-1","article-title":"The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs","volume":"40","author":"Nagayasu","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0005-2736(95)00159-Z","article-title":"Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery","volume":"1239","author":"Lasic","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2006.12.002_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-5793(92)80947-F","article-title":"Gelation of liposome interior. A novel method for drug encapsulation","volume":"312","author":"Lasic","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2006.12.002_bib33","series-title":"Liposomes useful for drug delivery, W.O. 2005\/107712","author":"Hong","year":"2005"},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0005-2736(90)90091-2","article-title":"Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients","volume":"1025","author":"Mayer","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0005-2736(93)90256-Y","article-title":"Optimization of the retention properties of vincristine in liposomal systems","volume":"1152","author":"Boman","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2006.12.002_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","article-title":"Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer","volume":"1663","author":"Charrois","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jconrel.2006.12.002_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-3565(24)35297-8","article-title":"Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors","volume":"292","author":"Lim","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2006.12.002_bib38","first-page":"566","article-title":"Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone","volume":"281","author":"Lim","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2006.12.002_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2006.12.002_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0169-409X(95)00030-B","article-title":"Liposome circulation time and tumor targeting: implications for cancer chemotherapy","volume":"16","author":"Gabizon","year":"1995","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365906006985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365906006985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T08:39:48Z","timestamp":1736671188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365906006985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0168365906006985"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2006.12.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}